Provided by Tiger Trade Technology Pte. Ltd.

Commercial Metals

64.87
-1.4400-2.17%
Post-market: 64.870.00000.00%19:30 EDT
Volume:1.49M
Turnover:97.27M
Market Cap:7.20B
PE:12.32
High:68.70
Open:67.41
Low:64.39
Close:66.31
52wk High:84.87
52wk Low:53.08
Shares:111.05M
Float Shares:109.72M
Volume Ratio:1.09
T/O Rate:1.36%
Dividend:0.74
Dividend Rate:1.14%
EPS(TTM):5.26
EPS(LYR):0.7400
ROE:13.79%
ROA:6.32%
PB:1.59
PE(LYR):87.66

Loading ...

Commercial Metals Co : UBS Raises to Buy From Neutral

THOMSON REUTERS
·
May 14

Press Release: Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Dow Jones
·
May 14

UBS Upgrades Commercial Metals to Buy From Neutral, Adjusts Price Target to $89 From $79

MT Newswires Live
·
May 14

Commercial Metals Raised to Buy From Neutral by UBS

Dow Jones
·
May 14

U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology

Reuters
·
May 14

Commercial Metals upgraded to Buy from Neutral at UBS

TIPRANKS
·
May 14

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

GlobeNewswire
·
May 13

CoinMarketCap warns users over fake CMC token scam

cryptonews
·
May 13

CMC Corp Sees FY Net Y2.20B

Dow Jones
·
May 13

Fake 'CMC Tokens' Trigger Crypto Scam Alert From CoinMarketCap

utoday
·
May 13

Press Release: Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Dow Jones
·
May 13

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 13

Press Release: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 12

Press Release: AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Dow Jones
·
May 12

Table: CMC Magnetics Apr Rev NT$601.8M Vs NT$611.1M

Dow Jones
·
May 11

CMC Corp Sees 1H Parent Pretax Y2.00B

Dow Jones
·
May 07

CMC Markets Executives Acquire Shares Under UK Incentive Plan

TIPRANKS
·
May 06

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 06

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

GlobeNewswire
·
May 05

YD Bio Limited Reports Full Year 2025 Financial Results

GlobeNewswire
·
May 01